1.38
-0.07 (-4.83%)
| Previous Close | 1.45 |
| Open | 1.43 |
| Volume | 45,801 |
| Avg. Volume (3M) | 155,379 |
| Market Cap | 161,148,112 |
| Price / Earnings (Forward) | 116.28 |
| Price / Sales | 3.90 |
| Price / Book | 2.72 |
| 52 Weeks Range | |
| Earnings Date | 25 Feb 2025 |
| Profit Margin | -47.87% |
| Operating Margin (TTM) | -49.16% |
| Diluted EPS (TTM) | -0.130 |
| Quarterly Revenue Growth (YOY) | 43.00% |
| Total Debt/Equity (MRQ) | 19.39% |
| Current Ratio (MRQ) | 3.99 |
| Operating Cash Flow (TTM) | -12.57 M |
| Levered Free Cash Flow (TTM) | -10.21 M |
| Return on Assets (TTM) | -16.80% |
| Return on Equity (TTM) | -35.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Distribution (AU) | Mixed | Mixed |
| Medical Distribution (Global) | Bearish | Bearish | |
| Stock | CYCLOPHARM FPO [CYC] | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.0 |
| Average | 0.38 |
|
Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism, and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment. |
|
| Sector | Healthcare |
| Industry | Medical Distribution |
| Investment Style | Small Core |
| % Held by Insiders | 48.68% |
| % Held by Institutions | 21.62% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |